MENU
PBE
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
PBE
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for PBE with price predictions
Oct 01, 2026

PBE in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 08, 2026

PBE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 41 cases where PBE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

PBE moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +0.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in 261 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for PBE moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 18 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 63 cases where PBE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBE as a result. In 72 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for PBE turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for PBE entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF (PBE) ETF is 29.01B. The market cap for tickers in the group ranges from 736.73M to 226.05B. AMGN holds the highest valuation in this group at 226.05B. The lowest valued company is COLL at 736.73M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF (PBE) ETF was 14%. For the same ETF, the average monthly price growth was 41%, and the average quarterly price growth was 286%. UTHR experienced the highest price growth at 21%, while ACAD experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF (PBE) ETF was 7%. For the same stocks of the ETF, the average monthly volume growth was 10% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 45
Price Growth Rating: 47
SMR Rating: 68
Profit Risk Rating: 70
Seasonality Score: 21 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com
PBE in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 08, 2026